Biocon Chairperson and MD, Kiran Majumdar Shaw confirmed that she has IPO on her plate. And yes, she confirmed that Biocon is getting a USD 150 million investment from Goldman Sachs. Shaw confirmed that the pre-IPO investment is crucial for Biocon to reach the target of USD 1 billion in the next two years.
Goldman Sachs To Invest In Biocon Biologics
Biocon Ltd. on November 7 announced that its board had approved Goldman Sachs investment of USD150 million to its subsidiary Biocon Biologics Ltd. As per the terms of the contract, Goldman Sachs is offered optionally convertible debentures of post-money equity valuation of USD 3.94 billion.
Commenting on the news, Shaw said it is a part of their strategic plan. The capital injection is scheduled at the time when Biocon is preparing to become a global leader, is a real boost to the company’s image. Biocon Biologics also declared its plans to make an IPO debut.
A Little Background Of Biocon Biologics
Biocon Biologics is a leading name in producing biosimilar drugs. The company has one of the largest portfolios globally that extent patients’ access to advanced therapies. It manufactures a plethora of Rh-Insulin, insulin analogs, monoclonal antibodies, therapeutic proteins for oncology, immunology, and other chronic disease drugs.
The company has an entire spectrum of insulin in its pipeline. Recently, Biocon has commercialised Insulin Glargine, making it the only company from India to provide affordable access to three products: biosimilar monoclonal antibody (Trastuzumab), a therapeutic protein (Pegfilgrastim) and an Insulin analog (Glargine) to US patients.
Biocon Biologics is India’s largest biopharmaceutical company. The company started its journey in 1978 played a key role in transforming India’s image as a pioneer and leader in manufacturing a wide range of affordable biopharmaceutical drugs. Biocon produces drugs toward prevention, alleviation, and treatment of chronic diseases, increasing assess to cutting-edge biosimilar medicine to over million patients.
Investment from Goldman Sachs will enable Biocon to elevate R&D and high-quality manufacturing as well as its footprint in the global market.
Highlights of the deal
Talking about the deal, MD, Kiran Majumdar Shaw said the IPO offering would be much bigger in size. The pre-IPO investment will help set a benchmark in the market about the company’s worth. She added that having big marquee investors like Goldman Sachs, Tata Capital, and True North assisted Biocon in explaining its journey in value creation in a better way, will play a pivotal role during IPO launch.
The biosimilar drugs sector is poised to see robust growth in near future, assisted by a collaborative regulatory pathway, budget sustainability in the healthcare sector, and improved patients’ access to treatment. In this case, Biocon Biologics is excellently placed to drive the growth.
Enjoy Zero Brokerage on Equity Delivery
Join our 1.75 Cr+ happy customers
Enjoy Zero Brokerage on